Every one of those 1 sits in a single category, funding. Akero Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Red Queen Therapeutics, all published on July 15, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Red Queen Therapeutics
Every one of those 1 sits in a single category, funding. Akero Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Red Queen Therapeutics, all published on July 15, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Red Queen Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
The Cayman court ruling ousting Seth Harrison from the helm of Apple Tree Partners’ $1.5 billion biotech fund threatens the financial lifeline for companies like Intergalactic, Red Queen, and Akero. With the fund in Chapter 11 and control contested, clinical-stage biotechs may face delayed rounds, disrupted operations, and investor uncertainty.